UY36198A - Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo - Google Patents

Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo

Info

Publication number
UY36198A
UY36198A UY0001036198A UY36198A UY36198A UY 36198 A UY36198 A UY 36198A UY 0001036198 A UY0001036198 A UY 0001036198A UY 36198 A UY36198 A UY 36198A UY 36198 A UY36198 A UY 36198A
Authority
UY
Uruguay
Prior art keywords
compounds
useful
sumo
heteroarilo
enzyme inhibitors
Prior art date
Application number
UY0001036198A
Other languages
English (en)
Spanish (es)
Inventor
England Dylan
Freeze Scott
Hu Zhigen
Mcintyre Charles
Mizutani Hirotake
Ono Koji
Xu He
Matthew O Duffey
Steven P Langston
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55019950&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY36198(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of UY36198A publication Critical patent/UY36198A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/535—Organo-phosphoranes
    • C07F9/5352—Phosphoranes containing the structure P=C-
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
UY0001036198A 2014-07-01 2015-06-30 Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo UY36198A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462019756P 2014-07-01 2014-07-01
US201562185678P 2015-06-28 2015-06-28

Publications (1)

Publication Number Publication Date
UY36198A true UY36198A (es) 2016-01-29

Family

ID=55019950

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036198A UY36198A (es) 2014-07-01 2015-06-30 Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo

Country Status (39)

Country Link
US (6) US9683003B2 (enExample)
EP (3) EP3901159A1 (enExample)
JP (4) JP6603712B2 (enExample)
KR (1) KR102491125B1 (enExample)
CN (1) CN106999479B (enExample)
AU (1) AU2015284135B2 (enExample)
BR (1) BR112016030787B1 (enExample)
CA (1) CA2953132C (enExample)
CL (1) CL2016003398A1 (enExample)
CR (1) CR20170021A (enExample)
CY (1) CY1122808T1 (enExample)
DK (1) DK3164130T3 (enExample)
DO (1) DOP2016000339A (enExample)
EA (1) EA034119B1 (enExample)
EC (1) ECSP17006751A (enExample)
ES (1) ES2754359T3 (enExample)
GE (1) GEP20197047B (enExample)
HR (1) HRP20191979T1 (enExample)
HU (1) HUE045748T2 (enExample)
IL (1) IL249820B (enExample)
LT (1) LT3164130T (enExample)
ME (1) ME03574B (enExample)
MX (1) MX376054B (enExample)
MY (1) MY183649A (enExample)
NZ (1) NZ728162A (enExample)
PE (1) PE20170520A1 (enExample)
PH (1) PH12016502595B1 (enExample)
PL (1) PL3164130T3 (enExample)
PT (1) PT3164130T (enExample)
RS (1) RS59474B1 (enExample)
SG (1) SG11201610476VA (enExample)
SI (1) SI3164130T1 (enExample)
SM (1) SMT201900600T1 (enExample)
TN (1) TN2016000581A1 (enExample)
TW (1) TWI680970B (enExample)
UA (1) UA122963C2 (enExample)
UY (1) UY36198A (enExample)
WO (1) WO2016004136A1 (enExample)
ZA (1) ZA201700386B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013123169A1 (en) 2012-02-17 2013-08-22 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
EP2879681A4 (en) 2012-08-03 2015-12-23 Millennium Pharm Inc INDOINDUBSTITUTED PYRROLOPYRIMIDINYL HIBITORS OF UBA6
JP6603712B2 (ja) 2014-07-01 2019-11-06 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｓｕｍｏ活性化酵素の阻害薬として有用なヘテロアリール化合物
US10465447B2 (en) 2015-03-12 2019-11-05 Baker Hughes, A Ge Company, Llc Cutting elements configured to mitigate diamond table failure, earth-boring tools including such cutting elements, and related methods
TWI870767B (zh) 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
BR112019006414A2 (pt) 2016-10-03 2019-06-25 Janssen Pharmaceutica Nv análogos de carbanucleosídeos de sistema de anel monocíclico e bicíclico substituídos para uso como inibidores de prmt5
CN110382707A (zh) 2017-02-27 2019-10-25 詹森药业有限公司 生物标志在鉴定将对用prmt5抑制剂治疗有响应的癌症患者中的用途
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
US10400517B2 (en) 2017-05-02 2019-09-03 Baker Hughes, A Ge Company, Llc Cutting elements configured to reduce impact damage and related tools and methods
EP3684363A4 (en) 2017-09-21 2021-05-12 Millennium Pharmaceuticals, Inc. CO-CRYSTALLINE FORMS OF ((1S, 2S, 4R) -4- {4 - [(1S) -2,3-DIHYDRO-1H-INDÉN-1-YLAMINO] -7H-PYRROLO [2,3-D] PYRIMIDIN -7-YL} -2-HYDROXYCYCLOPENTYL) METHYLSULFAMATE, THEIR FORMULATIONS AND USES
WO2019110734A1 (en) 2017-12-08 2019-06-13 Janssen Pharmaceutica Nv Novel spirobicyclic analogues
US20210015915A1 (en) 2018-03-23 2021-01-21 Takeda Pharmaceutical Company Limited Sting modulator compounds with sulfamate linkages, and methods of making and using
WO2019204354A1 (en) * 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
US12097199B2 (en) 2018-07-09 2024-09-24 Takeda Pharmaceutical Company Limited Administration of SUMO-activating enzyme inhibitor and anti-CD20 antibodies
US10570668B2 (en) 2018-07-27 2020-02-25 Baker Hughes, A Ge Company, Llc Cutting elements configured to reduce impact damage and mitigate polycrystalline, superabrasive material failure earth-boring tools including such cutting elements, and related methods
CN109354569A (zh) * 2018-11-27 2019-02-19 常州大学 一种1,3-二溴-4-氟苯的制备方法
JP2022521972A (ja) * 2019-02-26 2022-04-13 ミレニアム ファーマシューティカルズ， インコーポレイテッド アジュバントとして有用な化合物
EP3930719B1 (en) * 2019-02-27 2025-08-20 Takeda Pharmaceutical Company Limited Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
EP3782702A1 (en) * 2019-08-21 2021-02-24 AC BioScience SA Compounds and use thereof for the treatment of infectious diseases and cancer
CN112402608B (zh) * 2020-11-30 2021-09-07 深圳先进技术研究院 5-烷氧基吲哚-3-乙烯基喹啉盐作为靶向可迁移光敏剂的应用
WO2021203001A1 (en) * 2020-04-03 2021-10-07 Millennium Pharmaceuticals, Inc. Method of treating patients infected with a viral infection with an inhibitor of small ubiquitin like modifier activating enzyme
KR20230010659A (ko) * 2020-05-15 2023-01-19 다케다 야쿠힌 고교 가부시키가이샤 Sumo-활성화 효소 억제제 및 항-cd38 항체의 투여
MX2023009131A (es) 2021-02-05 2023-09-19 Baker Hughes Oilfield Operations Llc Elementos de corte para herramientas de perforación de tierra, y métodos para fabricar herramientas de perforación de tierra.
CN113173852B (zh) * 2021-04-26 2022-07-12 深圳市华先医药科技有限公司 二氟丙二酸酯类化合物的制备方法
WO2023073645A1 (en) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
US11920409B2 (en) 2022-07-05 2024-03-05 Baker Hughes Oilfield Operations Llc Cutting elements, earth-boring tools including the cutting elements, and methods of forming the earth-boring tools
CN119585283A (zh) 2022-09-30 2025-03-07 微境生物医药科技(上海)有限公司 作为sumo活化酶抑制剂的化合物
CN120112536A (zh) * 2022-11-11 2025-06-06 微境生物医药科技(上海)有限公司 作为sumo活化酶抑制剂的化合物
WO2024110863A1 (en) 2022-11-22 2024-05-30 Takeda Pharmaceutical Company Limited Process and intermediates for preparing ((1r,2s,4r)-4-((5-(4-((r)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl)-5-methylthiophene-2-carbonyl)pyrimidin-4-yl)amino)-2-hydroxycyclopentyl)methyl sulfamate
CN117209449B (zh) * 2023-09-14 2025-11-28 上海毕得医药科技股份有限公司 一种2-(三氟甲基)噻唑类化合物的合成方法
NL2035852B1 (en) 2023-09-21 2025-03-28 Academisch Ziekenhuis Leiden Enhancement of t cell mediated therapies
CN119371416B (zh) * 2024-12-23 2025-05-30 上海达歌生物医药科技有限公司 一种通过氧杂环丁烷开环以构建4-取代异香豆素及其类似物的合成方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
WO1997005132A1 (en) 1995-07-28 1997-02-13 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
CA2477795A1 (en) 2002-02-28 2003-09-12 Kandasamy Sakthivel Nucleoside 5'-monophosphate mimics and their prodrugs
CA2481855A1 (en) * 2002-04-10 2003-10-23 Ortho-Mcneil Pharmaceutical, Inc. Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
US7527966B2 (en) 2002-06-26 2009-05-05 Transgenrx, Inc. Gene regulation in transgenic animals using a transposon-based vector
US7291603B2 (en) 2002-07-24 2007-11-06 Ptc Therapeutics, Inc. Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
AU2003261237A1 (en) 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
MXPA05002572A (es) 2002-09-04 2005-09-08 Schering Corp Compuestos pirazolo[1,5-a]pirimidinas como inhibidores de cinasa depentes de ciclina.
MXPA05002573A (es) 2002-09-04 2005-09-08 Schering Corp Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina.
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
AU2003291024A1 (en) 2002-11-13 2004-06-03 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
US20070179161A1 (en) 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
EP1680431A1 (en) 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
EP1690863A1 (en) 2003-11-26 2006-08-16 Dainippon Sumitomo Pharma Co., Ltd. Novel condensed imidazole derivative
WO2006002284A1 (en) 2004-06-22 2006-01-05 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
DK1848718T3 (da) 2005-02-04 2012-08-27 Millennium Pharm Inc E1 aktiveringsenzymhæmmere
US7642266B2 (en) 2005-10-06 2010-01-05 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
PT1989206E (pt) 2006-02-02 2012-10-15 Millennium Pharm Inc Inibidores da enzima de ativação e1
US8008307B2 (en) * 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
BRPI0715176A8 (pt) * 2006-08-08 2018-04-10 Millennium Pharm Inc compostos de heteroarila utéis como inibidores de enzimas de ativação e1
WO2008154642A2 (en) 2007-06-12 2008-12-18 Achaogen, Inc. Antibacterial agents
RU2553476C2 (ru) 2007-08-02 2015-06-20 Миллениум Фармасьютикалз, Инк. Способ синтеза ингибиторов е1-активирующего фермента
US9216983B2 (en) 2007-12-21 2015-12-22 Board Of Regents, University Of Texas System Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
CA2734487A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP5654990B2 (ja) 2008-08-20 2015-01-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アゾ置換ピリジンおよびピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
EP2326626B1 (en) 2008-08-20 2013-10-16 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8697694B2 (en) 2008-08-20 2014-04-15 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010039548A2 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
SG175929A1 (en) 2009-05-14 2011-12-29 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
ES2608670T3 (es) 2009-08-17 2017-04-12 Memorial Sloan-Kettering Cancer Center Derivados de 2-(pirimidin-5-il)-tiopirimidina como moduladores de Hsp70 y Hsc70 para el tratamiento de trastornos proliferativos
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
WO2011103441A1 (en) 2010-02-18 2011-08-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AU2010347233B2 (en) 2010-03-01 2015-06-18 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
PT2598483T (pt) 2010-07-29 2020-10-12 Rigel Pharmaceuticals Inc Compostos heterocíclicos de ativação de ampk e métodos de utilização dos mesmos
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
CN103889988B (zh) 2011-08-24 2018-05-04 米伦纽姆医药公司 Nedd8-活化酶的抑制剂
WO2013066729A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
WO2013123169A1 (en) 2012-02-17 2013-08-22 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
JP6378759B2 (ja) * 2013-07-02 2018-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｓｕｍｏ活性化酵素阻害剤として有用なヘテロアリール化合物
US20150087673A1 (en) 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
TR201911140T4 (tr) 2013-10-21 2019-08-21 Merck Patent Gmbh Btk inhibitörleri olarak heteroaril bileşikleri ve bunların kullanımları.
WO2015110999A1 (en) 2014-01-24 2015-07-30 Piramal Enterprises Limited Ezh2 inhibitors and uses thereof
JP6603712B2 (ja) 2014-07-01 2019-11-06 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｓｕｍｏ活性化酵素の阻害薬として有用なヘテロアリール化合物

Also Published As

Publication number Publication date
US20200085821A1 (en) 2020-03-19
KR102491125B1 (ko) 2023-01-20
JP2020023538A (ja) 2020-02-13
ME03574B (me) 2020-07-20
EP3164130A4 (en) 2018-02-14
IL249820B (en) 2019-09-26
AU2015284135B2 (en) 2019-11-28
MX376054B (es) 2025-03-07
US10335410B2 (en) 2019-07-02
EP3901159A1 (en) 2021-10-27
MY183649A (en) 2021-03-05
PH12016502595B1 (en) 2021-09-10
ZA201700386B (en) 2018-11-28
BR112016030787A2 (pt) 2017-08-22
CL2016003398A1 (es) 2017-12-29
CR20170021A (es) 2017-04-04
SI3164130T1 (sl) 2019-12-31
LT3164130T (lt) 2019-11-25
US20180311239A1 (en) 2018-11-01
US10780090B2 (en) 2020-09-22
CN106999479B (zh) 2021-07-16
BR112016030787A8 (pt) 2021-07-20
US20220331316A1 (en) 2022-10-20
PH12016502595A1 (en) 2017-04-24
ECSP17006751A (es) 2017-02-24
GEP20197047B (en) 2019-12-10
PL3164130T3 (pl) 2020-02-28
ES2754359T3 (es) 2020-04-17
EA034119B1 (ru) 2019-12-30
US20170002032A9 (en) 2017-01-05
IL249820A0 (en) 2017-02-28
CA2953132C (en) 2023-04-11
EP3164130A1 (en) 2017-05-10
US20160009744A1 (en) 2016-01-14
RS59474B1 (sr) 2019-12-31
HUE045748T2 (hu) 2020-01-28
EP3517112B1 (en) 2021-04-07
TW201613903A (en) 2016-04-16
TN2016000581A1 (en) 2018-04-04
EA201790108A1 (ru) 2017-07-31
JP2021178869A (ja) 2021-11-18
EP3164130B1 (en) 2019-08-07
TWI680970B (zh) 2020-01-01
US9683003B2 (en) 2017-06-20
EP3517112A1 (en) 2019-07-31
WO2016004136A1 (en) 2016-01-07
SG11201610476VA (en) 2017-01-27
BR112016030787B1 (pt) 2022-12-20
PE20170520A1 (es) 2017-05-24
JP2024012558A (ja) 2024-01-30
MX2016016993A (es) 2017-02-27
CY1122808T1 (el) 2021-05-05
US20170216290A1 (en) 2017-08-03
CA2953132A1 (en) 2016-01-07
JP6603712B2 (ja) 2019-11-06
JP2017524734A (ja) 2017-08-31
US9962386B2 (en) 2018-05-08
NZ728162A (en) 2023-06-30
AU2015284135A1 (en) 2017-02-09
DOP2016000339A (es) 2017-03-15
CN106999479A (zh) 2017-08-01
UA122963C2 (uk) 2021-01-27
KR20170032334A (ko) 2017-03-22
SMT201900600T1 (it) 2020-01-14
DK3164130T3 (da) 2019-10-28
US20230293522A1 (en) 2023-09-21
PT3164130T (pt) 2019-11-18
HRP20191979T1 (hr) 2020-02-07

Similar Documents

Publication Publication Date Title
UY36198A (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
ECSP16083602A (es) Derivados de quinolina como inhibidores smo
MX2016013052A (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4.
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
MX377845B (es) Inhibidores de calicreína plasmática humana.
MX2014015185A (es) Derivados deuterados de ruxolitinib.
EA201691442A1 (ru) N-азаспироциклоалканзамещенные n-гетероарильные соединения и композиции для ингибирования активности shp2
EA201690129A1 (ru) Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
EA201692480A1 (ru) Фармацевтическая композиция
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
MX373603B (es) Activador de canales de kcnq2-5.
UY36228A (es) Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
EA201591259A1 (ru) Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
IN2015DN01329A (enExample)
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
AR088735A1 (es) Compuestos de tienopirimidina que son inhibidores de canal de potasio
DOP2016000325A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
MX385938B (es) Nuevo derivado de catecol y composición farmacéutica que comprende el mismo.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220705